PositiveID Corporation to Present at the Aegis Capital Corp. 2015 Growth Conference on October 8th
September 29, 2015 08:30 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., Sept. 29, 2015 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced...
Battelle National Biodefense Institute Awarded 10-Year National Biodefense Analysis and Countermeasures Center Contract
September 23, 2015 10:22 ET
|
Battelle
FREDERICK, MD--(Marketwired - September 23, 2015) - The Battelle National Biodefense Institute has been awarded a new 10-year management and operations contract for the National Biodefense Analysis...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon(R) and Ampligen(R) Against the Ebola Virus
November 03, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has been informed by USAMRIID scientists that they have in-vitro data...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
September 08, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that the Company and USAMRIID scientists have agreed to test...
Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
August 20, 2014 13:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 20, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of...
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
August 15, 2014 07:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
July 01, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 1, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data Presented at 8th Annual NIH Counteract Meeting in Denver
...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure
June 18, 2014 10:39 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 18, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced the publication of data from animal model studies demonstrating the efficacy of...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
June 02, 2014 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 2, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
May 15, 2014 19:03 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...